Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights
Clene Inc. (CLNN)
Company Research
Source: GlobeNewswire
Initiated discussions with FDA regarding accelerated approval pathway for CNM-Au8® for the treatment of ALS with the objective of submitting an NDA in 2024Released long-term data from the open-label extension of the HEALEY ALS Platform Trial in which CNM-Au8 demonstrated statistically significant reductions of plasma neurofilament light chain (NfL) levels at 76 weeks relative to placebo (18 months from randomization, p=0.023) as well as a 60% decreased risk of long-term all-cause mortality using rank-preserving structural failure time model analysis (18 months, p=0.0167)Demonstrated a statistically significant survival benefit (p=0.0001) in Expanded Access Program (EAP) participants (n=220) treated with CNM-Au8 compared to historical ALS disease progression controls with decreased risk of all-cause mortality ranging from 57%-68% Reported additional long-term data from the Phase 2 VISIONARY-MS trial in which CNM-Au8 treatment was associated with vision improvement as measured by low co
Show less
Read more
Impact Snapshot
Event Time:
CLNN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLNN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLNN alerts
High impacting Clene Inc. news events
Weekly update
A roundup of the hottest topics
CLNN
News
- IBN Announces From Lab to Launch Podcast Featuring Clene Inc. CEO Rob Etherington [Yahoo! Finance]Yahoo! Finance
- IBN Announces From Lab to Launch Podcast Featuring Clene Inc. CEO Rob EtheringtonGlobeNewswire
- ‘Liquid gold' could bring new hope to multiple sclerosis patients, study suggests: ‘Profound benefit' [FOX News]FOX News
- Bullish Clene Insiders Loaded Up On US$9.58m Of Stock [Yahoo! Finance]Yahoo! Finance
- Clene Inc. (NASDAQ: CLNN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.MarketBeat
CLNN
Earnings
- 11/7/23 - Beat
CLNN
Sec Filings
- 5/1/24 - Form 4
- 4/26/24 - Form 8-K
- 4/17/24 - Form ARS
- CLNN's page on the SEC website